A number of cardiovascular diseases have been linked to high plasma levels of lipoprotein (a), and some other diseases are thought to be independently predicted. Recent research indicates that the Chinese population's Lp(a) concentration levels differ significantly from those of other populations. A high level of Lp(a) in the Chinese population indicates a higher rate of thrombogenicity, platelet aggregation, and revascularization following PCI. Higher levels of Lp(a) have been linked to an increased risk of atherosclerotic cardiovascular disease (ASCVD) in the Chinese population, according to studies. More specifically, higher levels of Lp(a) have been linked to an increased risk of coronary heart disease, severe aortic valve stenosis, deep vein thrombosis in spinal cord injury patients, central vein thrombosis in hemodialysis patients, and stroke in Chinese populations.
Lp (a) may also play a crucial role in a number of other conditions, including cancer, type 2 diabetes, and the metabolic syndrome, according to new and consistent data retrieved from a number of clinical trials. This audit investigates the clinical and epidemiological connections among Lp(a), cardiovascular sicknesses and diabetes in the Chinese populace as well as likely Lp(a) hidden systems in these illnesses. To better comprehend the role of Lp(a) in the Chinese population's cardiovascular diseases and diabetes, however, additional research is required.